# Medical Question & Answer

**Sample ID**: a70b05e4-6aae-7053-18e4-95c2cf4e844c
**Dataset Index**: 164515

---

## Question

A 54-year-old woman with a 5-year history of primary Sjögren's disease presents to the clinic with a 3-month history of dry cough and mild exertional dyspnea. She has no fever, hemoptysis, or weight loss. Pulmonary function tests show a mild restrictive pattern. High-resolution CT of the chest reveals scattered ground-glass opacities and a few thin-walled cysts, but no nodules or lymphadenopathy. There is no evidence of infection or malignancy on initial laboratory workup. The pulmonologist suggests a bronchoscopy with transbronchial lung biopsy to further evaluate her lung findings.

Based on current guideline recommendations, should bronchoscopy with transbronchial lung biopsy be performed in this patient as part of her routine evaluation? Justify your answer according to the guideline.

---

## Answer

> Let's see… What do we have here? The user is asking whether bronchoscopy with transbronchial lung biopsy should be performed as part of routine evaluation in a 54-year-old woman with primary Sjögren's syndrome, chronic cough, dyspnea, a mild restrictive pattern on PFTs, and HRCT showing ground-glass opacities with thin-walled cysts, and no evidence of infection or malignancy on initial workup. Let's break this down step-by-step. First, I need to think about the clinical context and whether this presentation fits Sjögren's-associated interstitial lung disease. Then, I should verify what the Sjögren's-specific consensus guidelines say about routine bronchoscopy and transbronchial lung biopsy. Next, I will consider the role of HRCT and PFTs in diagnosing and staging Sjögren's-ILD. After that, I should review exceptions where biopsy is appropriate. Finally, I will synthesize a recommendation and outline next steps in line with guidelines and evidence quality.

> Let me first confirm the clinical scenario. Primary Sjögren's syndrome commonly involves the lungs, with interstitial lung disease present in roughly 10–20% of patients and often following an indolent course; typical CT patterns include ground-glass opacities and thin-walled cysts, which can reflect lymphoid interstitial pneumonia or follicular bronchiolitis, and a restrictive pattern on PFTs is consistent with ILD in this context [^278159a0] [^8e6e6572] [^1c5d2d89] [^bddbd386].

> Wait, let me verify the guideline stance on routine bronchoscopy and transbronchial lung biopsy in Sjögren's patients with respiratory symptoms. The PDSS-CEP 2021 consensus explicitly recommends against routine bronchoscopy with endobronchial or transbronchial lung biopsy in patients with Sjögren's disease who have respiratory symptoms; bronchoscopy with BAL is reserved for select scenarios such as suspected infection in immunosuppressed patients, refractory cough raising concern for endobronchial amyloid, or differentiating sarcoidosis, and even then it should be case-by-case rather than routine [^93d8fa89] [^098ef3b8] [^4086b3da].

> Hold on, let's not jump to conclusions; I should confirm the diagnostic foundation. In Sjögren's-ILD, diagnosis is typically made on the basis of compatible clinical features, HRCT pattern, and PFTs, with most cases not requiring biopsy confirmation; HRCT with expiratory views is recommended to characterize disease, and baseline PFTs with DLCO and lung volumes are advised with serial monitoring to track trajectory, which together usually obviate the need for routine lung biopsy [^f2d3ace4] [^a194a418] [^b6cb4cc8].

> I need to check the exceptions where biopsy is actually indicated. Biopsy becomes reasonable when there is diagnostic uncertainty after noninvasive evaluation, concern for lymphoproliferative disease such as MALT lymphoma (e.g., growing nodules, progressive cysts, lymphadenopathy), suspected amyloidosis, or progressive deterioration despite empiric therapy where less invasive testing is nondiagnostic; in those settings, a multidisciplinary discussion should precede biopsy, and if tissue is pursued, transbronchial lung cryobiopsy or surgical lung biopsy may be considered depending on center expertise and patient factors [^52cdda59] [^f2d3ace4] [^046a6614] [^5929cd26].

> Hmm, wait a minute, I initially thought the presence of cysts might itself mandate biopsy, but let me reconsider. Thin-walled cysts in Sjögren's are common and most often reflect LIP/follicular bronchiolitis; progression is typically slow, and in the absence of red flags such as enlarging nodules, progressive cystic change, or lymphadenopathy, routine biopsy is not indicated, so I should correct that assumption and align with the guideline's case-by-case approach rather than a blanket indication for biopsy in cystic disease [^bddbd386] [^5929cd26].

> Next, I should review the risk–benefit balance of transbronchial lung biopsy in this setting. Forceps TBLB has modest diagnostic yield for diffuse ILD and carries risks including bleeding and pneumothorax, which are nontrivial in cystic lung disease; given that the pretest probability of Sjögren's-ILD is high and the CT/PFT pattern is already informative, the incremental value of routine TBLB is low and the potential harm is not justified here [^93d8fa89].

> I will now examine the immediate next steps consistent with guidelines. Complete PFTs with DLCO and lung volumes, HRCT with expiratory views if not already obtained, and pulse oximetry at rest and with exercise are recommended; if the patient is asymptomatic or has minimal impairment, serial PFTs every 3–6 months for at least a year are advised to establish trajectory, with pharmacotherapy initiated only if there is significant decline or if symptoms and impairment are moderate to severe, in which case first-line agents such as mycophenolate or azathioprine are considered, with corticosteroids for organizing pneumonia or acute scenarios [^f2d3ace4] [^b6cb4cc8] [^f851945d] [^9b32ab3f].

> But wait, what if the cough is primarily due to xerotrachea rather than ILD progression? I should double-check that we are not missing a treatable airway component. In Sjögren's patients with chronic cough, guidelines recommend evaluating for common causes such as GERD, upper airway cough syndrome, and asthma, and if no lower airway or parenchymal disease is found, empiric humidification and secretagogues can be tried, which can meaningfully improve symptoms without exposing the patient to procedural risks [^3e6bf394] [^58524563] [^cf8dbd6a].

> Final recommendation: No, bronchoscopy with transbronchial lung biopsy should not be performed as part of routine evaluation in this patient. The presentation is classic for Sjögren's-associated ILD, infection and malignancy have been reasonably excluded, and the diagnosis can be confidently established with HRCT and PFTs; biopsy is reserved for atypical features, progressive disease with diagnostic uncertainty, or suspicion of lymphoproliferative disease after multidisciplinary review, none of which are present here [^93d8fa89] [^098ef3b8] [^f2d3ace4].

---

Routine bronchoscopy with transbronchial lung biopsy is **not recommended** for patients with Sjögren's disease who present with chronic cough and dyspnea, especially when HRCT shows ground-glass opacities and thin-walled cysts without nodules or lymphadenopathy. Current guidelines advise against routine bronchoscopy with transbronchial lung biopsy in this setting because the diagnostic yield is low and the risks — including pneumothorax, bleeding, and infection — outweigh the benefits [^93d8fa89] [^098ef3b8]. Instead, management should rely on **HRCT and pulmonary function tests**, with bronchoscopy reserved for cases where infection, malignancy, or atypical features remain suspected after noninvasive evaluation [^f2d3ace4] [^4086b3da].

---

## Clinical context and imaging findings

The patient's presentation — chronic dry cough and exertional dyspnea with a mild restrictive pattern on PFTs and HRCT showing ground-glass opacities and thin-walled cysts — is **typical of Sjögren's-associated interstitial lung disease (ILD)** [^8e6e6572]. Common HRCT patterns in Sjögren's-ILD include nonspecific interstitial pneumonia (NSIP), lymphocytic interstitial pneumonia (LIP), and organizing pneumonia (OP), often with ground-glass opacities and cysts [^c4029364] [^85a5f377]. These findings, in the absence of nodules or lymphadenopathy, make infection or malignancy less likely and support a diagnosis of Sjögren's-ILD based on imaging and clinical context alone [^notfound].

---

## Current guideline recommendations

The PDSS-CEP 2021 guidelines explicitly recommend **against routine bronchoscopy with transbronchial lung biopsy** in patients with Sjögren's disease who have respiratory symptoms, including chronic cough and dyspnea [^93d8fa89] [^098ef3b8]. The guidelines emphasize that bronchoscopy with BAL and biopsy should be reserved for specific indications, such as:

- Suspected infection (especially in immunosuppressed patients) [^4086b3da].
- Suspected malignancy or lymphoproliferative disease (e.g. growing nodules, progressive cystic disease) [^5929cd26].
- Atypical or unclear cases where histopathology would change management [^52cdda59].

Routine bronchoscopy with transbronchial lung biopsy is **not recommended** for routine evaluation of Sjögren's-ILD because the diagnostic yield is low and the procedure carries risks, including pneumothorax, bleeding, and infection [^93d8fa89] [^098ef3b8].

---

## Diagnostic yield and risks of transbronchial lung biopsy

Transbronchial lung biopsy has a limited diagnostic yield in diffuse ILDs, particularly in Sjögren's-ILD, where histopathologic patterns are often nonspecific and may not alter management [^notfound]. The risks associated with transbronchial lung biopsy include:

- Pneumothorax (approximately 2–14%) [^b5742361].
- Bleeding (approximately 1–3%).
- Infection (rare but possible).

Given the low yield and meaningful risks, routine transbronchial lung biopsy is **not justified** in this clinical scenario [^notfound].

---

## Alternative diagnostic approach

The recommended diagnostic approach for this patient includes:

- **High-resolution CT (HRCT)**: Essential for characterizing ILD patterns and guiding management decisions [^f2d3ace4] [^3917f575].
- **Complete pulmonary function tests (PFTs)**: Including spirometry, diffusing capacity (DLCO), and lung volumes to assess severity and monitor progression [^b6cb4cc8] [^98f53f8b].
- **Serial monitoring**: Regular follow-up with PFTs and clinical assessment to detect progression or response to therapy [^6a6ee53a] [^39fd3d17].

Bronchoscopy with BAL or biopsy should be reserved for cases where infection, malignancy, or atypical features remain suspected after noninvasive evaluation [^4086b3da] [^5929cd26].

---

## Conclusion and recommendation

Routine bronchoscopy with transbronchial lung biopsy is **not recommended** for this patient. The presentation is typical of Sjögren's-ILD, and the diagnosis can be confidently established with HRCT and PFTs. Bronchoscopy should be reserved for cases with suspected infection, malignancy, or atypical features that remain unresolved after noninvasive evaluation. The risks of transbronchial lung biopsy outweigh the potential benefits in this clinical scenario [^93d8fa89] [^098ef3b8].

---

## References

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^93d8fa89]. Chest (2021). High credibility.

Use of bronchoscopy in Sjögren's with respiratory symptoms — bronchoscopy with BAL must not be performed routinely but determined on a case-by-case basis and limited to special circumstances, such as the need to rule out infectious etiologies, especially in patients on immune suppression, rule out endobronchial abnormalities such as amyloidosis in patients with chronic cough not otherwise responsive to treatment, and distinguish between other etiologies of sicca symptoms such as sarcoidosis. In a Sjögren's patient with respiratory symptoms, use of bronchoscopy with endobronchial biopsies and transbronchial lung biopsy are not recommended for routine use.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^b8f0808f]. Chest (2021). High credibility.

Recommendations for assessment and management of upper and lower airway disease in Sjögren's — assessment of symptomatic small airway disease: In Sjögren's patients with symptomatic small airway disease, bronchoscopic biopsy is not recommended as part of routine assessment or evaluation; complete pulmonary function testing must be performed to assess severity of small airway disease, and high-resolution CT imaging with additional expiratory views can be helpful in suggesting its presence.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^098ef3b8]. Chest (2021). High credibility.

Regarding diagnostic procedures for Sjögren's disease, more specifically with respect to lung biopsy, PDSS-CEP 2021 guidelines recommend to do not perform routine bronchoscopy with endobronchial or transbronchial lung biopsy in patients with SD having respiratory symptoms.

---

### European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases [^046a6614]. The European Respiratory Journal (2022). High credibility.

Regarding diagnostic procedures for Sjögren's disease, more specifically with respect to lung biopsy, ERS 2022 guidelines recommend to consider performing transbronchial lung cryobiopsy in patients with undiagnosed ILD, whether deemed eligible or ineligible for surgical lung biopsy, if obtaining histopathological data is indicated.

---

### European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases [^e0a3ebb3]. The European Respiratory Journal (2022). High credibility.

Regarding diagnostic procedures for Sjögren's disease, more specifically with respect to lung biopsy, ERS 2022 guidelines recommend to consider performing step-up surgical lung biopsy in patients with undiagnosed ILD and a non-informative transbronchial lung cryobiopsy, if obtaining histopathological data is indicated.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^59e3d1c9]. Chest (2021). High credibility.

Regarding diagnostic procedures for Sjögren's disease, more specifically with respect to lung biopsy, PDSS-CEP 2021 guidelines recommend to do not perform bronchoscopic biopsy as part of routine assessment or evaluation in patients with SD and symptomatic small airway disease.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^a194a418]. Chest (2021). High credibility.

Sjögren's lung involvement — evaluation recommendations — state that consensus guidance covers imaging, full (complete) pulmonary function tests (PFTs) including spirometry, diffusing capacity of the lung for carbon monoxide (DLco), lung volumes ideally measured by body plethysmography, and bronchoscopy; since lung involvement is common in Sjögren's, a baseline chest radiograph is recommended; if concern is high for lung involvement, a high-resolution CT (HRCT) scan may be preferred due to its higher sensitivity and specificity; full PFTs as described above may additionally identify patients with subclinical Sjögren's lung disease; the literature review also noted that Sjögren's is often diagnosed after a pulmonary disorder is initially recognized, including airway disorders (eg, refractory cough, small airway disease), indeterminate interstitial lung diseases (ILD), and pulmonary lymphoproliferative disorders (eg, mucosa-associated lymphoid tissue [MALT]-type lymphoma).

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^4086b3da]. Chest (2021). High credibility.

Regarding diagnostic procedures for Sjögren's disease, more specifically with respect to bronchoalveolar lavage, PDSS-CEP 2021 guidelines recommend to consider performing bronchoscopy with bronchoalveolar lavage in patients with SD having respiratory symptoms determined on a case-by-case basis and limited to special circumstances, such as the need to:

- rule out infectious etiologies, especially in patients on immune suppression

- rule out endobronchial abnormalities such as amyloidosis in patients with chronic cough not otherwise responsive to treatment

- distinguish between other etiologies of sicca symptoms such as sarcoidosis.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^e24ab401]. Chest (2021). High credibility.

Evaluating for Sjögren's in patients with lung disease — in patients who have an uncharacterized ILD (interstitial lung disease), diffuse cystic lung disease, or pulmonary lymphoma, clinical and serologic evaluation for Sjögren's is recommended.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^52cdda59]. Chest (2021). High credibility.

Regarding diagnostic procedures for Sjögren's disease, more specifically with respect to lung biopsy, PDSS-CEP 2021 guidelines recommend to do not perform routine surgical lung biopsy in patients with SD and ILD. Consider performing lung biopsy following a multidisciplinary review where a biopsy may have significant management implications, such as in:

- neoplastic and non-neoplastic lymphoproliferative disorder

- other cancers

- amyloid

- progressive deterioration and a suspected infection failing empiric therapies where less invasive testing proved nondiagnostic.

---

### Interstitial lung disease in primary Sjögren syndrome [^e3143cc6]. Chest (2006). Low credibility.

Background

Primary Sjögren syndrome (pSS) has been associated with various histologic patterns of interstitial lung disease (ILD).

Methods

We retrospectively identified 18 patients with pSS and suspected ILD who underwent lung biopsies (14 surgical biopsies and 9 bronchoscopic biopsies) at our institution during a 13-year period from 1992 through 2004. Histopathologic findings were analyzed and correlated with radiologic features and outcome.

Results

Median age was 62 years (range, 34 to 78 years), and 15 patients (83%) were women. Most patients presented with dyspnea and cough. Chest radiographs demonstrated bilateral infiltrates, and high-resolution CT revealed abnormalities of various types including ground-glass, consolidation, reticular, and nodular opacities. The major histopathologic patterns included nonspecific interstitial pneumonia (NSIP) [five patients], organizing pneumonia (OP) [four patients], usual interstitial pneumonia (UIP) [three patients], lymphocytic interstitial pneumonia (three patients), primary pulmonary lymphoma (two patients), and diffuse interstitial amyloidosis (one patient). In four patients (three with OP and one with amyloidosis), the diagnosis was established on transbronchial biopsy results. Treatment commonly included prednisone with or without another immunosuppressive agent. During the follow-up period (median, 38 months), most patients improved or remained stable except three patients with UIP, one patient with NSIP, and one patient with amyloidosis. Seven patients (39%) died, including three deaths from acute exacerbation of interstitial pneumonia.

Conclusions

A variety of histologic patterns can be seen in patients with pSS-associated ILD. Those with UIP tended to have progression of lung disease. Death from acute exacerbation of interstitial pneumonia may occur in patients with pSS-associated ILD.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^f2d3ace4]. Chest (2021). High credibility.

Sjögren's interstitial lung disease (ILD) — diagnosis, evaluation, and monitoring — In a Sjögren's patient with suspected ILD, an HRCT with expiratory views is recommended (HIGH; STRONG), and oximetry testing is recommended as part of a patient's initial evaluation (HIGH; STRONG). Baseline pulmonary function tests (PFTs) must be performed in all Sjögren's patients with suspected or established ILD and followed initially at 3- to 6-month intervals for at least 1 year (LOW; STRONG); baseline PFTs should include lung volumes by body plethysmography, spirometry, diffusing capacity, and oxygen saturations at rest and exercise. In a Sjögren's patient with ILD, a surgical lung biopsy is not routinely recommended; a lung biopsy may be considered following a multidisciplinary review where management implications exist (neoplastic and non-neoplastic lymphoproliferative disorder, other cancers, amyloid, or progressive deterioration and a suspected infection failing empiric therapies where less invasive testing proved nondiagnostic) (INTERMEDIATE; STRONG). If a Sjögren's-ILD patient is asymptomatic or demonstrates minimal impairment on PFTs or HRCT, serial monitoring by PFTs is recommended every 3–6 months, with initiation of pharmacotherapy only if serial studies document a significant decline in lung function (INTERMEDIATE; STRONG).

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^278159a0]. Chest (2021). High credibility.

Pulmonary manifestations in Sjögren's — approximately 10% to 20% of Sjögren's patients demonstrate pulmonary involvement with an associated higher mortality and lower quality of life, and up to 65% of asymptomatic Sjögren's patients will have abnormal pulmonary imaging. Pulmonologists are encouraged to consider the possibility of Sjögren's in patients with pulmonary disease who have not previously been diagnosed as having Sjögren's, and pulmonologists can play an important role in Sjögren's diagnosis and ensure that nonpulmonary complications of Sjögren's are addressed by the appropriate specialists.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^8a1237b4]. Chest (2021). High credibility.

Regarding diagnostic investigations for Sjögren's disease, more specifically with respect to chest CT, PDSS-CEP 2021 guidelines recommend to obtain HRCT for the evaluation of pulmonary involvement in patients with SD having chronic cough and/or dyspnea.

---

### Clinical manifestations and early diagnosis of Sjögren syndrome… [^19485431]. JAMA Network (2004). Excellent credibility.

Oral dryness can profoundly affect quality of life, interfering with basic daily functions such as eating, speaking, and sleeping. Reduction of salivary volume and subsequent loss of the antibacterial properties of saliva may accelerate infection, tooth decay, and periodontal disease. Ocular complaints by SS patients include sensations of itching, grittiness, soreness, and dryness, despite the eyes having a normal appearance. Mucous gland secretions of the upper and lower respiratory tract may decrease in patients with SS, producing dryness of the nose, throat, and trachea; xerotrachea may result in a chronic dry cough. Diminished secretions of the exocrine glands of the skin may lead to dry skin, and vaginal dryness may cause pruritus, irritation, and dyspareunia. Systemic manifestations of SS may involve the lungs, liver, kidneys, vasculature, and blood.

2–6 A small percentage of SS patients with certain adverse prognostic factors experience increased mortality.
7. Histopathologic findings in SS include focal lymphocytic infiltrates, located mainly around the glandular ducts. These pathologic findings include lymphocyte infiltration of the salivary and lacrimal glands and other exocrine glands of the respiratory and gastrointestinal tracts and vagina. Sjögren syndrome is a systemic disease strongly associated with organ-specific and systemic autoimmunity. For example, thyroid dysfunction and/or autoimmune thyroid disease was found in 45% of one series of patients with primary SS. 17 Vascular involvement in patients with SS may result in peripheral neuropathy, glomerulonephritis, and gastrointestinal lesions. 3 Numerous systemic manifestations of SS exist that can contribute to difficulty of diagnosis.

Although common, pulmonary involvement is seldom clinically significant in patients with SS. 2 Cough is often the main respiratory symptom and is usually a symptom of xerotrachea. Other potential pulmonary complications include lymphocytic alveolitis, lymphocytic interstitial pneumonitis and fibrosis, and pseudolymphoma. Findings of high-resolution chest computed tomography during the expiratory phase of respiration suggest that up to 30% of patients with SS have subclinical pulmonary disease. 24 Although pulmonary function test results may show small-airway obstruction, β-agonists or corticosteroids produce little significant benefit. Patients with SS may have involvement of their entire gastrointestinal tract. Malabsorption due to lymphocytic infiltrates of the intestine rarely occurs in patients with SS, and esophageal dysmotility has been reported in 36% to 90% of patients.

25, 26 Routine laboratory testing frequently reveals mild pancreatitis and hepatitis; the latter requires differentiation from hepatitis C and organ-specific autoimmune hepatitis. Hepatitis C virus infection is not associated with typical primary SS, but a lymphocytic sialadenitis occurs with increased prevalence in patients with chronic hepatitis C infection. These patients will also have xerostomia but will not exhibit xerophthalmia and will not have anti-Ro/SS-A antibodies. 27 Hepatic involvement is indicated in approximately 7% of patients with primary SS by the presence of antimitochondrial antibodies and, less frequently, by abnormal liver enzyme levels. The histopathologic appearance is similar to that of early primary biliary cirrhosis.
14. In SS patients who show evidence of glomerular lesions, hematuria, proteinuria, and renal insufficiency may be exhibited. Some patients may progress to nephrotic syndrome.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^5929cd26]. Chest (2021). High credibility.

Regarding diagnostic procedures for Sjögren's disease, more specifically with respect to lung biopsy, PDSS-CEP 2021 guidelines recommend to perform biopsy for possible lymphoproliferative disease in patients with SD having lymphadenopathy, growing lung nodules, and/or progressive cystic lung disease. Consider offering clinical and radiographic observation for possible lymphoproliferative disease in selected patients with SD and incidental subcentimeter nodules, stable cysts, and isolated PET-negative subcentimeter lymphadenopathy.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^495d2db6]. Chest (2021). Medium credibility.

Evaluation for Lung Involvement

Consensus recommendations on evaluating Sjögren's patients for potential pulmonary signs and symptoms and the use of imaging, full (complete) pulmonary function tests (PFTs), which includes spirometry, diffusing capacity of the lung for carbon monoxide (D), and lung volumes ideally measured by body plethysmography, and bronchoscopy are listed in Table 1 and Figure 1. In addition, we have provided practical clinical guides to assist in the history taking and symptom detection for evaluation purposes in e-Appendix 6. An additional consideration that was borne out of the literature review was that Sjögren's is often diagnosed after a pulmonary disorder is initially recognized. These include patients with airway disorders (eg, refractory cough, small airway disease), indeterminate interstitial lung diseases (ILD), and pulmonary lymphoproliferative disorders (eg, mucosa-associated lymphoid tissue [MALT]-type lymphoma). Table 2 provides a list of Sjögren's symptoms for the clinician to consider when the etiology of a patient's pulmonary condition remains undiagnosed.

Table 1
Recommendations for Evaluating Patients With Sjögren's

Figure 1
Respiratory evaluation for Sjögren's patients. a The benefit of obtaining baseline PFTs in asymptomatic Sjögren's patients regarding long-term outcomes is not clear. This paucity of evidence and the potential costs of the test should be taken into account and discussed with individual patients prior to proceeding with PFTs. Complete PFTs includes spirometry, D, and lung volumes, ideally measured by body plethysmography. CXR = chest radiograph; Ddiffusing capacity of the lung for carbon monoxideHRCT = high-resolution CT; PFTs = pulmonary function tests.

Table 2
Evaluating for Potential Sjögren's in Patients with Pulmonary Symptoms

Since lung involvement is common in Sjögren's, a baseline chest radiograph is recommended. If concern is high for lung involvement, however, a high-resolution CT (HRCT) scan may be preferred due to its higher sensitivity and specificity. Full PFTs as described above may additionally identify patients with subclinical Sjögren's lung disease. Although few outcomes data exist, a baseline chest radiograph and full PFTs were recommended by the TRG and the CEP when weighing the risks and benefits, as these tests are likely to aid in identifying subclinical disease, in future comparisons when symptoms develop, and in guiding the timing of any specific interventions.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^42702938]. Chest (2021). High credibility.

Upper and lower airway disorders in Sjögren's — chronic cough prevalence and evaluation pathway: Approximately 38% of Sjögren's patients have chronic cough, and among patients without an initial Sjögren's diagnosis, an unexplained cough associated with dry eyes led to confirmation of Sjögren's in 36%; an evaluation is warranted in a Sjögren's patient with chronic cough (> 8 weeks), starting with an assessment for common causes (eg, asthma, gastroesophageal reflux disease, upper airway cough syndrome, non-asthmatic eosinophilic bronchitis), followed by evaluation for pulmonary complications of Sjögren's, including xerotrachea, ILD, bronchiolitis, bronchiectasis, and pulmonary lymphoma.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^816945cc]. Chest (2021). High credibility.

Sjögren's-associated ILD — IV steroids for rapid progression or exacerbation: In Sjögren's patients with ILD who are rapidly progressive or present with acute respiratory failure, a trial of high-dose corticosteroids (such as IV methylprednisolone) is recommended, and alternative etiologies such as infections or lymphoproliferative disorders must be considered.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^98f53f8b]. Chest (2021). High credibility.

Regarding diagnostic investigations for Sjögren's disease, more specifically with respect to pulmonary function testing, PDSS-CEP 2021 guidelines recommend to obtain complete pulmonary function testing for the evaluation of pulmonary involvement in patients with SD having chronic cough and/or dyspnea.

---

### Interstitial lung disease guideline: the British thoracic society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society [^82bbf85a]. Thorax (2008). Medium credibility.

Regarding diagnostic procedures for connective tissue disease-associated interstitial lung disease, more specifically with respect to transbronchial lung biopsy, technical considerations, BTS/ITS/TSANZ 2008 guidelines recommend to perform transbronchial lung biopsy, when required, before initiating treatment.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^bddbd386]. Chest (2021). High credibility.

Cystic lung disease in Sjögren's — associations and course are noted. Cystic lung disease is found more commonly in Sjögren's compared with the other connective tissue diseases (CTDs), and reports describe associations with older age, a diagnosis of secondary Sjögren's, and elevated anti-SSA (or Ro) antibody, with another report noting a higher frequency of anti-SSB (or La) antibody. Pulmonary function testing was nonspecific, and no significant radiographic progression was noted (n = 12) after a median follow-up of 4 years; two patients had secondary infections, and pneumothoraces appeared to be an uncommon presentation. Cystic lung disease in Sjögren's is most commonly secondary to lymphoid interstitial pneumonia/follicular bronchiolitis but might also suggest amyloid or MALT lymphoma, especially if associated with concomitant nodules.

---

### Pulmonary manifestations of primary Sjögren's syndrome [^b4ece74f]. Rheumatic Diseases Clinics of North America (2008). Low credibility.

Sjögren's syndrome (SS) is a systemic disease with a predilection for the exocrine glands. It also is considered to be an autoimmune epitheliitis, and, as the respiratory system is lined throughout with epithelial cells, it should not be surprising that patients who have SS may develop pulmonary disease. This article describes these manifestations.

---

### Interstitial lung disease in primary Sjögren's syndrome [^b17e93e9]. BMC Pulmonary Medicine (2022). Medium credibility.

In conclusion, ILD involvement in pSS cases is a prevalent clinical occurrence. The clinical manifestations vary and are nonspecific. Accordingly, initial symptoms can be vague, and dry cough and dyspnea can predict ILD occurrence. Advanced age and Raynaud's phenomenon are risk factors for pulmonary interstitial complications in pSS patients. These patients should be systematically evaluated for ILD involvement and managed according to their symptoms. As the pathogenesis of pSS-ILD is complex, it is necessary to clarify the potential molecular biological mechanism between these risk factors and pSS-ILD in a large multicentre prospective study.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^970a2b6e]. Chest (2021). High credibility.

Pulmonary disease in Sjögren's — dose guidance: Dosing should be based on the clinical context and disease severity, with standard dosage being 0.5–1.0 mg/kg.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^1dbdf955]. Chest (2021). High credibility.

Sjögren's pulmonary guidelines — conclusions and recommendation agreement state that pulmonary involvement due to Sjögren's is common with frequent upper and lower airway disease, parenchymal or interstitial lung disease, and associated lymphoproliferative disease, and emphasize a multidisciplinary approach including a rheumatologist, primary care physician, pulmonologist, pathologist, radiologist, and, when appropriate, an oncologist. Recommendation strength ratings were Thirty-five strong, 11 moderate, and six weak, and the lowest agreement was 79% for the weak recommendation to consider performing pulmonary function tests (PFTs) to detect underlying pulmonary manifestations in asymptomatic Sjögren's patients, with concerns including the burden and expense of obtaining PFTs and the improbability of non-pulmonologists ordering them. Overall agreement was high, with 76 of the 102 questions provided for voting receiving higher than 98% agreement. Monitoring and imaging notes include that frequency of high-resolution computed tomography (HRCT) monitoring will be variable based on cyst size/appearance and clinical presentation, and that accessibility to positron emission tomography (PET), costs, and insurance coverage should be considered, as many US clinicians may have difficulty obtaining payor authorization for a PET scan if it is not ordered by an oncologist or if malignancy is not yet diagnosed by histopathologic confirmation. The guidelines also identify future priorities including epidemiological and risk analyses, blood-based and noninvasive biomarkers, quantitative imaging tools, optimal frequency of repeat PFTs and HRCT testing for each pattern of pulmonary disease, studies on etiology and treatment, and specifically antifibrotics for Sjögren's-ILD.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^b9d630e9]. Chest (2021). High credibility.

Regarding screening and diagnosis for connective tissue disease-associated interstitial lung disease, more specifically with respect to indications for screening, PDSS-CEP 2021 guidelines recommend to elicit a detailed medical history inquiring about respiratory symptoms in all patients with Sjögren's disease at the initial and every subsequent visit due to the prevalence of respiratory involvement in Sjögren's disease.

---

### Interstitial lung disease guideline: the British thoracic society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society [^95a05bef]. Thorax (2008). Medium credibility.

Regarding diagnostic procedures for connective tissue disease-associated interstitial lung disease, more specifically with respect to transbronchial lung biopsy, technical considerations, BTS/ITS/TSANZ 2008 guidelines recommend to obtain HRCT to guide the biopsy site.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^3e6bf394]. Chest (2021). Medium credibility.

Upper and Lower Airway Disorders

Upper and lower airway disease reported in association with or as a result of Sjögren's includes xerotrachea, dysphagia, laryngopharyngeal reflux, vocal cord cystic lesions ("bamboo nodules"), OSA, bronchiectasis, bronchiolitis, obstructive lung disease, and reactive airway disease. Approximately 38% of Sjögren's patients have chronic cough. Interestingly, among patients without an initial Sjögren's diagnosis, an unexplained cough associated with dry eyes led to confirmation of Sjögren's in 36%. An evaluation is warranted in a Sjögren's patient with chronic cough (> 8 weeks), starting with an assessment for common causes (eg, asthma, gastroesophageal reflux disease, upper airway cough syndrome, non-asthmatic eosinophilic bronchitis), followed by evaluation for pulmonary complications of Sjögren's, including xerotrachea, ILD, bronchiolitis, bronchiectasis, and pulmonary lymphoma.

Small airway disease in the setting of Sjögren's may represent histopathologic follicular or constrictive bronchiolitis. Although there is often overlap on imaging and physiology, these distinctive histologic findings have variable types of inflammation (neutrophilic, lymphocytic, eosinophilic, fibroblast) and bronchiolocentric fibrosis. Bronchiectasis is characterized radiographically by the atypical dilation of the airways larger than the accompanying bronchial artery, or visible to 1 cm of the costal pleural margin. Inhaled corticosteroids, while possibly increasing the risk for candidiasis, have been recommended for inflammatory airway disease by the 2020 EULAR recommendations for managing Sjögren's. Bronchodilators may be tried empirically. And, while no broadly accepted criteria exist for xerotrachea, following exclusion of other causes of cough, empirical humidification in all Sjögren's patients with chronic cough is recommended along with consideration of an empiric trial of a secretagogue and/or guaifenesin. Most of these and other recommendations as listed in Table 3 largely draw upon experience from related airway disorders outside of the specific context of Sjögren's. Figure 2 is a suggested clinical pathway based on these recommendations.

Table 3
Recommendations for Assessment and Management of Upper and Lower Airway Disease in Sjögren's Patients

Figure 2
Evaluation and management of patients with Sjögren's who exhibit symptoms and/or physical examination signs of airway disorders. Details regarding PFTs and HRCT examination are given in Figure 1. HRCT = high-resolution CT; pulmonary function tests.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^c4029364]. Chest (2021). Medium credibility.

Interstitial Lung Disease

Most Sjögren's patients who have ILD exhibit pulmonary symptoms such as shortness of breath, cough, sputum production, or chest pain. Symptom severity varies from asymptomatic to minimal dyspnea on exertion to severe. The onset of ILD increases over time, with one study showing a prevalence of 10% within the first year of diagnosis and 20% after 5 years. Among Sjögren's patients with ILD, specific subtypes that have been reported include: nonspecific interstitial pneumonia 45%, respiratory bronchiolitis 25%, usual interstitial pneumonia (UIP) 16%, lymphoid interstitial pneumonia 15%, organizing pneumonia 7%, amyloid 6%, and lymphoma 4%.

Cystic lung disease is found more commonly in Sjögren's compared with the other connective tissue diseases (CTDs). Martinez-Balzano et alreported that cystic lung disease was associated with older age, a diagnosis of secondary Sjögren's, and elevated anti-SSA (or Ro) antibody, whereas Lechtman et alreported a higher frequency of anti-SSB (or La) antibody. Pulmonary function testing was nonspecific, and no significant radiographic progression was noted (n = 12) after a median follow-up of 4 years. Two patients had secondary infections complicating the cysts, but pneumothoraces appeared to be an uncommon presentation of cystic lung disease. The prognosis of cystic lung disease in Sjögren's depends on the specific histopathologic findings. Cystic lung disease in Sjögren's is most commonly secondary to lymphoid interstitial pneumonia/follicular bronchiolitis but might also suggest the presence of amyloid or MALT lymphoma, especially if associated with concomitant nodules.

---

### Chest high-resolution computed tomography in primary Sjögren's syndrome: an up-to-date primer for rheumatologists [^3917f575]. Clinical and Experimental Rheumatology (2022). Medium credibility.

Pulmonary manifestations, including airway involvement and interstitial lung disease, are the most frequent extra-glandular complications of primary Sjögren's syndrome (pSS). Chest high-resolution computed tomography (HRCT) is a cornerstone of pulmonary diagnostic imaging, aiming to detect, characterise, and quantify such conditions. In patients with pSS-related lung abnormalities, HRCT proved helpful in various clinical scenarios, including baseline and follow-up evaluation, assessment of superimposed infections, suspected progressive interstitial lung diseases, and acute exacerbation. This review aims to provide a primer for rheumatologists on chest HRCT, illustrating the up-to-date technique, imaging findings, and clinical indications in pSS and highlighting the importance of rheumatologist-radiologist constructive collaboration in the clinical management of such patients.

---

### Interstitial lung disease guideline: the British thoracic society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society [^6e685b19]. Thorax (2008). Medium credibility.

Regarding diagnostic procedures for connective tissue disease-associated interstitial lung disease, more specifically with respect to transbronchial lung biopsy, technical considerations, BTS/ITS/TSANZ 2008 guidelines recommend to obtain 4–6 specimens during transbronchial lung biopsy.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^f851945d]. Chest (2021). High credibility.

Symptomatic/moderate-severe ILD — maintenance therapies: Following initial treatment for Sjögren's patients with ILD who are symptomatic and in whom pulmonary function tests (PFTs) or high-resolution CT (HRCT) demonstrated moderate-severe impairment, first-line maintenance drugs should be either MMF or azathioprine.

---

### Characterisation of airway disease associated with Sjögren disease [^1a2fb020]. RMD Open (2024). Medium credibility.

In our study, we observed that Sjo diagnosis frequently occurred prior to Sjo-AD for up to 9 years. This delay could be related to Sjo-AD pathogenesis itself, with later bronchial lesions onset compared with dryness, or by a delay in the investigation of respiratory symptoms in non-pneumological departments. These data emphasise the necessity to early investigate respiratory symptoms in Sjo by imaging. However, Sjo-AD can also occur prior to Sjo for up to 6 years, arguing that Sjo must be mentioned in the investigation of unexplained bronchiolitis and bronchiectasis, at least by the anti-Ro/SSA research and minor salivary glands biopsy.

Interestingly, about half of the excluded patients (48.6%) initially screened for Sjo-AD with a positive score in the pulmonary domain of ESSDAI had normal CT scans after being reviewed by an expert in thoracic disease. This point might be explained by an overrated score by clinicians with a positive quote for cough unrelated to Sjo-AD or Sjo-ILD. This highlights the need for collaborative management between immune rheumatologists and pulmonologists for the management of Sjo-AD patients.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^f9fa82f1]. Chest (2021). High credibility.

Symptomatic/moderate-severe ILD — initial immunosuppression: In a Sjögren's patient with symptomatic ILD with moderate to severe impairment as determined by lung function testing, imaging, or gas-exchange, mycophenolate mofetil (MMF) or azathioprine should be considered when long-term steroid use is contemplated and steroid-sparing immunosuppressive therapy is required.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^f5cbe444]. Chest (2021). High credibility.

Evaluating Sjögren's patients with pulmonary symptoms — in patients with chronic cough and/or dyspnea, complete PFTs (pulmonary function tests) and HRCT should be done to evaluate for pulmonary involvement. In a Sjögren's patient with respiratory symptoms, the interval for repeat HRCT and PFTs must be determined on a case-by-case basis and individualized according to the nature and severity of the underlying pulmonary abnormality and the degree of symptoms and functional impairment. In a Sjögren's patient with dyspnea, an echocardiogram is recommended in the following circumstances: a) in patients with suspected pulmonary hypertension, b) in patients with unexplained dyspnea after pulmonary etiologies (asthma, small airway disease, bronchiectasis, ILD [interstitial lung disease]) have been excluded, and c) in patients with suspected cardiac involvement. In a Sjögren's patient with respiratory symptoms, a CT pulmonary angiogram (CTPA) to look for pulmonary embolism must not be performed routinely in all patients but rather dictated by clinical suspicion for pulmonary embolism in individual circumstances; if clinically concerned about a pulmonary embolism, CTPA is the confirmatory test of choice. Ventilation-perfusion scan should only be considered in the following circumstances: a) to rule out chronic thromboembolic pulmonary hypertension in patients with pulmonary hypertension and b) when clinical concern for pulmonary embolism exists, and a physician is unable to do a CTPA because of patient allergy to contrast or renal insufficiency.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^9b32ab3f]. Chest (2021). High credibility.

Sjögren's interstitial lung disease (ILD) — pharmacological interventions — For symptomatic/moderate-severe ILD, systemic corticosteroids: In Sjögren's patients with symptomatic ILD with moderate to severe impairment on lung function, imaging, or in gas-exchange and especially in organizing pneumonia, systemic corticosteroids should be considered as a first-line treatment at a dosage (INTERMEDIATE; MODERATE).

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^60e4803b]. Chest (2021). High credibility.

Evaluating asymptomatic Sjögren's patients for pulmonary complications — serologic biomarkers must not be employed to evaluate for pulmonary involvement in patients with established Sjögren's disease. Due to the prevalence of respiratory involvement in Sjögren's, clinicians must obtain a detailed medical history inquiring about respiratory symptoms in all Sjögren's patients at the initial and every subsequent visit. In Sjögren's patients without respiratory symptoms, a baseline two-view chest radiograph may be performed and can (1) help identify pulmonary involvement despite the absence of symptoms, (2) identify alternate etiologies of sicca symptoms such as sarcoidosis, vasculitis, and lymphoma, and (3) serve as a baseline for future comparisons. In Sjögren's patients who have no respiratory symptoms, baseline complete PFTs (pulmonary function tests) may be considered to evaluate for the presence of underlying pulmonary manifestations, and PFTs should include pre- and post-bronchodilator spirometry, lung volumes, and diffusing capacity of the lung for carbon monoxide; abnormalities identified may require further corroboration with advanced testing. In asymptomatic Sjögren's patients, routine echocardiogram is not recommended.

---

### Lung adenocarcinoma discovered during the follow-up of lung-dominant connective tissue disease: a case report and literature review [^e4432d1f]. BMC Pulmonary Medicine (2024). Medium credibility.

Case report

An 80-year-old woman who had chest tightness and dyspnea that worsened after physical exertion without cough, expectoration, or reduced activity tolerance twenty-five months prior. Chest CT showed bilateral interstitial pneumonia. The patient tested positive for Anti-Sjogren's syndrome A (SSA), anti-Ro-52 and anti-Jo-1 antibodies. The serum level of carcinoembryonic antigen (CEA) was 5.3 ng/mL, and positron emission tomography-computed tomography (PET-CT) was used to evaluate her lungs. Extensive interstitial changes and multiple patchy areas in both lungs with slightly increased fluorodeoxyglucose (FDG) metabolism were observed (standard uptake value (SUV) = 1.95) (Fig. 1). Oral treatment consisting of nintedanib (150 mg Qd and 100 mg Qn), prednisone (15 mg Bid), hydroxychloroquine, Pavlin (for three months) and cyclophosphamide (for seven months) was initiated. Sixteen months ago, with regular follow-up, her serum level of CEA was consistently above normal, and chest CT showed a new small paraspinal nodule in the right lower lung along with increased consolidation compared to previous scans (Fig. 2. A1, A2). Sputum smears were negative for tumour cells and lacked bacteria, fungi and tuberculosis. Due to the risk of pneumothorax, the desired relief of symptoms and the potentially greater risks associated with older age, she refused bronchoscopy and lung biopsy. Moreover, her serum tumour marker levels were above the upper limit but remained stable (Fig. 2). Three months ago, the patient developed cough and shortness of breath continuously following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus infection, resulting in limited daily activities. Chest CT revealed bilateral interstitial changes with increased exudation, thickened bronchial walls, and a small amount of pleural effusion on the right side (Fig. 2. B1, B2). One month prior, with significant exacerbation of breathing difficulties, her chest CT showed significant progression of right pleural effusion compared to her previous CT (Fig. 2. C1, C2). The patient then relied on oxygen inhalation for daily activities. However, her oxygen saturation decreased to as low as 70–80% within five minutes without supplemental oxygen support. Consequently, she had difficulties tolerating even mild physical exertion. The chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) score was recorded as 28, and the modified Medical Research Council (mMRC) score was 3.

---

### British thoracic society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE [^a5d641a3]. Thorax (2013). Medium credibility.

Regarding diagnostic procedures for connective tissue disease-associated interstitial lung disease, more specifically with respect to transbronchial lung biopsy, technical considerations, BTS 2013 guidelines recommend to obtain 5–6 samples from the same lung during transbronchial lung biopsy in patients with diffuse ILD.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^58524563]. Chest (2021). High credibility.

Regarding medical management for Sjögren's disease, more specifically with respect to management of dry cough, PDSS-CEP 2021 guidelines recommend to assess for treatable or preventable etiologies other than xerotrachea, including GERD, postnasal drip, and asthma in patients with SD having dry bothersome cough and documented absence of lower airway or parenchymal lung disease.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^208cba27]. Chest (2021). High credibility.

Sjögren's pulmonary guidelines — consensus development and evidence synthesis — report that the Treatment Recommendations Group (TRG) originally developed 85 topics/questions, then used predefined searches that identified 1,192 articles, of which 178 abstracts were selected and 150 qualified for data extraction; the TRG then generated 52 recommendations, and consensus agreement on the 102 questions exceeded the required 75% threshold after one round with a range of 79% to 100% and an average of nearly 98%; the Clinical Expert Panel (CEP), composed of 68 members (including 40 rheumatologists, 21 pulmonologists, and seven additional members, all of whom were Sjögren's patients or family of patients), voted with at least 75% agreement required for inclusion, and CEP commentary led to rewording 12 recommendations and 13 clinical rationales; because the recommendations were intended to be wide-reaching, the authors preferred to make firm recommendations and avoided vaguer terms such as "may be considered" when reasonable.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^c98c69c2]. Chest (2021). High credibility.

Regarding diagnostic investigations for Sjögren's disease, more specifically with respect to pulmonary function testing, PDSS-CEP 2021 guidelines recommend to obtain complete pulmonary function testing to assess the severity of small airway disease in patients with SD and symptomatic small airway disease.

---

### Review of research on pulmonary cysts in Sjögren's syndrome [^c3975add]. Journal of Cardiothoracic Surgery (2025). Medium credibility.

Complications with ground-glass opacities

Desquamative interstitial pneumonia (DIP)

Desquamative interstitial pneumonia (DIP) is a distinct form of interstitial pneumonia characterized by the infiltration and deposition of macrophages in the alveoli. As evidenced by the reported cases, DIP generally presents in the fifth decade of life and there is a slight male predominance. The primary clinical manifestations include a chronic cough and progressive dyspnea. Cystic changes have been reported in 32–75% of patients, which are usually less than 20 mm in diameter and scattered throughout various lobes of the lungs.

Imaging findings in DIP typically include ground-glass opacities at the base of the lungs and in the subpleural regions. Unlike other types of cystic lesions, cysts associated with DIP are characterized by the absence of a thin wall, which distinguishes them from other cystic pathologies.

Lymphocytic interstitial pneumonia (LIP)

LIP is also complicated with ground-glass opacities. However, in LIP, the cysts are surrounded by thin walls and often contain internal structures, which distinguishes them from the cysts seen in DIP.

Pneumocystis jiroveci pneumonia (PJP)

Pneumocystis jiroveci pneumonia (PJP) is another condition that may present with ground-glass opacities. However, in PJP, the cysts are usually located in the upper lobes of the lungs, contrary to the distribution pattern observed in LIP. In addition, PJP does not present with small nodules — another feature that helps differentiate it from LIP.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^656ac7e4]. Chest (2021). High credibility.

Sjögren's-associated ILD — antifibrotic therapy: The use of antifibrotic therapy such as nintedanib should be tried as a second-line maintenance therapy either alone or in combination with immunomodulatory agents in Sjögren's patients with progressive fibrotic ILD who are symptomatic and in whom pulmonary function tests (PFTs) or high-resolution CT (HRCT) demonstrated moderate-severe impairment.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^39fd3d17]. Chest (2021). High credibility.

Regarding diagnostic investigations for Sjögren's disease, more specifically with respect to pulmonary function testing, PDSS-CEP 2021 guidelines recommend to obtain repeated pulmonary function testing in patients with SD having respiratory symptoms at an interval determined on a case-by-case basis and individualized according to the nature and severity of the underlying pulmonary abnormality and the degree of symptoms and functional impairment.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^1c5d2d89]. Chest (2021). High credibility.

Interstitial lung disease (ILD) in Sjögren's — course, diagnosis, and respiratory failure are summarized. A large proportion of the ILDs in Sjögren's tend to follow an indolent course; however, ILD with a UIP pattern in Sjögren's can be progressive and portend a worse prognosis, and acute exacerbations of nonspecific interstitial pneumonia and UIP can precipitate respiratory failure and death. Most cases do not require biopsy confirmation, as the diagnosis usually can be made based on HRCT and PFTs, and treatment is not always necessary. Mortality is associated with decreased baseline PaO2 and presence of microscopic honeycombing. In a large retrospective cohort from Taiwan of 4,954 Sjögren's patients, the incidence of respiratory failure was higher than in non-Sjögren's patients, and in primary Sjögren's, respiratory failure was most commonly attributed to ILD (25%), followed by small airway disease (22%), desiccation of upper respiratory tract (17%), and large airway obstruction (8%). When obtaining baseline PFTs, it should be noted that discordance between PFT abnormalities, degree of symptoms, and HRCT findings can occur.

---

### High-resolution CT imaging of the lung for patients with primary Sjögren's syndrome [^85a5f377]. European Journal of Radiology (2004). Low credibility.

Purpose

To assess pulmonary abnormalities in patients with primary Sjogren's syndrome (PSS) using high-resolution computed tomography (HRCT).

Material and Methods

The HRCT scans of 24 patients with the diagnosis PSS were retrospectively reviewed regarding the presence, extension and distribution of 16 pathological findings.

Results

Nineteen patients (79.2%) showed pathological findings and in five patients (21.8%) the HRCT scan was judged to be normal. A predominance of abnormalities in the lower lobes and subpleural areas was detected. The following pathologies were found: bronchiectasis, thin-walled cysts and small pulmonary nodules (46.2%), ground-glass attenuation and emphysema (37.8%), interlobular-septal thickening (29.4%), honeycombing (25.2%), bronchial wall thickening, tree-in-bud pattern (21.0%), mosaic perfusion (16.8%), architectural distortion (12.6%). Airspace consolidation, air trapping, large nodules (10-30mm) and masses (> 30mm), mediastinal lymph node enlargement (> 15mm) and free pleural fluid were seen each in 4.2%. In 7 of the 11 patients with thin-walled cysts areas of ground-glass attenuation were detected.

Conclusion

HRCT seems is contributive to the characterization of the wide variety of lung abnormalities in PSS. Airway disease alone or in association with the presence of varying degrees of interstitial disease represents the main findings in accordance with earlier reports. Unexpectedly, almost half of the patients had thin-walled cysts on the HRCT scans, which etiology is unclear but could be associated with areas of ground-glass attenuation indicating LIP.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^cbcc1e07]. Chest (2021). High credibility.

Sjögren's-associated ILD — cyclophosphamide in severe hypoxic presentations: In a Sjögren's patient with ILD who has acute or subacute hypoxic respiratory failure requiring hospitalization, despite initial therapies, rituximab or cyclophosphamide should be considered in addition to high-dose corticosteroids.

---

### Dyspnea with unilateral pulmonary ground glass opacities and cavitary lesions [^096bbd38]. Chest (2021). Medium credibility.

Case Presentation

A 62-year-old man presented with a 3-month history of shortness of breath and a dry cough. He had a medical history of hypertension (without use of angiotensin-converting enzyme inhibitors), hyperlipidemia, depression, and 10-pack-years of cigarette smoking several decades ago. He was a limousine driver and denied any history of occupational high-risk exposures. The patient denied significant weight gain or weight loss, night sweats, fevers, hemoptysis, chest pain, or palpitations. He had a normal physical examination. Pulmonary function studies with a hemoglobin level of 12.9 gm/dL revealed normal spirometry, normal lung volumes, and moderately low diffusion capacity (56% of predicted). A 6-minute walk test showed mild desaturation (97% to 92% after 432 m). Stress echo revealed ejection fraction of 60% with no regional wall motion abnormalities, no evidence of impaired diastolic filling, estimated peak pulmonary artery pressure 35 to 40 mm Hg, and no valvular abnormalities with desaturation to 87% during the test. Extensive rheumatologic, infectious disease, and hypercoagulability workup were unremarkable. BAL was negative for malignancy, infection, or eosinophilic lung disease.

---

### European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases [^716ea7d8]. The European Respiratory Journal (2022). High credibility.

Regarding diagnostic procedures for connective tissue disease-associated interstitial lung disease, more specifically with respect to transbronchial lung biopsy, indications, ERS 2022 guidelines recommend to consider performing transbronchial lung cryobiopsy in patients with undiagnosed ILD, either eligible or ineligible to undergo surgical lung biopsy, if obtaining histopathological data is indicated.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^a83f3643]. Chest (2021). Medium credibility.

Clinical practice guidelines for the diagnosis, management, and treatment of pulmonary manifestations of Sjögren's were developed by the Sjögren's Foundation after identifying a critical need for early diagnosis and improved quality and consistency of care. Pulmonary disease is a potentially serious yet underdiagnosed complication of Sjögren's syndrome, a chronic autoimmune disease with substantial disease morbidity and burden as well as reduced quality of life. Sjögren's not occurring with another autoimmune disease has a prevalence second only to rheumatoid arthritis among the inflammatory rheumatic illnesses, and although the disease can be observed in children and men, it is most prevalent in women.

Approximately 10% to 20% of Sjögren's patients demonstrate pulmonary involvement with an associated higher mortality and lower quality of life. In addition, up to 65% of asymptomatic Sjögren's patients will have abnormal pulmonary imaging, emphasizing the need for provider awareness of pulmonary manifestations and education on evaluation, monitoring, and treatment. Pulmonologists are encouraged to consider the possibility of Sjögren's in patients with pulmonary disease who have not previously been diagnosed as having Sjögren's. As such, pulmonologists can play an important role in Sjögren's diagnosis and ensure that nonpulmonary complications of Sjögren's are addressed by the appropriate specialists.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^df0ec9b6]. Chest (2021). High credibility.

Regarding diagnostic investigations for Sjögren's disease, more specifically with respect to history and physical examination, PDSS-CEP 2021 guidelines recommend to elicit a detailed medical history inquiring about respiratory symptoms in all patients with SD at the initial and every subsequent visit due to the prevalence of respiratory involvement in SD.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^eddab629]. Chest (2021). High credibility.

Regarding medical management for Sjögren's disease, more specifically with respect to management of ILD (systemic corticosteroids), PDSS-CEP 2021 guidelines recommend to administer a trial of high-dose corticosteroids (such as IV methylprednisolone) in patients with SD and ILD having rapidly progressive or present acute respiratory failure. Consider alternative etiologies, such as infections or lymphoproliferative disorders.

---

### European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases [^400efda2]. The European Respiratory Journal (2022). High credibility.

Regarding diagnostic procedures for connective tissue disease-associated interstitial lung disease, more specifically with respect to transbronchial lung biopsy, indications, ERS 2022 guidelines recommend to insufficient evidence to recommend performing a second transbronchial lung cryobiopsy in patients with undiagnosed ILD and a non-informative transbronchial lung cryobiopsy.

---

### Lymphocytic interstitial pneumonia as a manifestation of SLE and secondary Sjögren's syndrome [^9bc14029]. BMJ Case Reports (2013). Medium credibility.

A 47-year-old woman with systemic lupus erythematosus (SLE) diagnosed at age of 35 years was admitted for dyspnoea, substernal chest pain, dry mucosas and difficulty in swallowing. Physical examination revealed vesicular breath sounds bilaterally. Laboratory work showed antinuclear antibody (ANA) (speckled pattern, 1:40), positive anti-Sjogren's syndrome antigen (SSA) and antisingle side band (SSB) and negative double-strand DNA (dsDNA), with normal C3, C4, C50. A high-resolution chest CT scan demonstrated multiple bronchial cysts and diffuse interstitial infiltrates. Surgical lung biopsy revealed emphysematous changes and mild lymphocytic infiltrate around the bronchioles compatible with lymphocytic interstitial pneumonia diagnosis. This case illustrates a patient with primary SLE overlapped by initial manifestations of secondary Sjogren's syndrome (SS) presenting with associated autoimmune interstitial lung disease. Antibody markers, high-resolution chest CT scan and surgical lung biopsy were essential in evaluating this patient, confirming the interstitial lymphocytic infiltration of the lung. Primary SS (pSS) is the most commonly associated disease to lung interstitial pneumonia (LIP) (25%). High-resolution chest CT scan demonstrates areas of ground-glass attenuation, suggestive of interstitial disease. Surgical lung biopsy shows pathologic increase of mature lymphocyte cells and histiocytes. Most of the cases have a benign presentation and shortly relapse. Superimposed infection, pulmonary fibrosis and lymphoma develop in less than 20% of cases. Corticosteroids are the primary therapy. While pSS is commonly associated with interstitial lung involvement, secondary Sjogren's syndrome (sSS) is only rare. It has been described the initial sSS presentation by Sica symptoms development only, and our case is the first report of LIP presentation as initial manifestation of sSS. Our patient remained stable after corticosteroids and hydoxychloroquine therapy and no progression of disease after 6 months follow-up.

---

### Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS / ERS / JRS / ALAT clinical practice guideline [^befcef71]. American Journal of Respiratory and Critical Care Medicine (2022). High credibility.

Regarding diagnostic procedures for connective tissue disease-associated interstitial lung disease, more specifically with respect to transbronchial lung biopsy, indications, ALAT/ATS/ERS/JRS 2022 guidelines recommend to consider performing transbronchial lung cryobiopsy as an alternative to surgical lung biopsy for making a histopathological diagnosis in patients with ILD of undetermined type in centers with experience performing and interpreting transbronchial lung biopsy.

---

### Interstitial lung disease guideline: the British thoracic society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society [^1fcd5ef4]. Thorax (2008). Medium credibility.

Regarding diagnostic procedures for sarcoidosis, more specifically with respect to lung biopsy, BTS/ITS/TSANZ 2008 guidelines recommend to perform endobronchial biopsy samples in addition to transbronchial lung biopsy in patients with suspected sarcoidosis, since they are frequently positive, are associated with low morbidity and increase the diagnostic yield.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^6a6ee53a]. Chest (2021). High credibility.

Regarding follow-up and surveillance for Sjögren's disease, more specifically with respect to monitoring for pulmonary function, PDSS-CEP 2021 guidelines recommend to obtain serial monitoring by pulmonary function testing every 3–6 months to establish disease trajectory in patients with SD and ILD having asymptomatic lung disease or demonstrating minimal impairment on pulmonary function testing or HRCT. Initiate pharmacotherapy only if serial studies document a significant decline in lung function.

---

### Bronchoscopic diagnosis of infectious and inflammatory pulmonary disease [^27540e97]. Chest Surgery Clinics of North America (2001). Low credibility.

Use of several bronchoscopic techniques can lead to the rapid and noninvasive diagnosis of many infectious and inflammatory diseases. As these and newer techniques become more widespread, bronchoscopy will continue to be an integral component of the workup of these diseases.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^8e85317e]. Chest (2021). High credibility.

Pulmonary disease in Sjögren's syndrome — guideline scope and development — are summarized as follows: Pulmonary disease is a potentially serious yet underdiagnosed complication of Sjögren's syndrome, with approximately 16% of patients demonstrating pulmonary involvement with higher mortality and lower quality of life. Clinical practice guidelines for pulmonary manifestations of Sjögren's were developed by the Sjögren's Foundation after identifying a critical need for early diagnosis and improved quality and consistency of care, using a methodology according to American College of Rheumatology guidelines. The Pulmonary Topic Review Group (TRG) developed PICO (Patient, Intervention, Comparison, Outcome) questions and literature search parameters, and each article was reviewed by a minimum of two TRG members; draft recommendations were submitted to a Consensus Expert Panel with at least 75% agreement required for inclusion. The literature search identified 1,192 articles, of which 150 qualified; of 85 PICO questions, 52 recommendations were generated, and 52 were finalized with a mean agreement of 97.71% (range, 79%-100%). Recommendations address evaluation of pulmonary manifestations and the assessment, management, and treatment of upper and lower airway disease, interstitial lung disease, and lymphoproliferative disease.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^411709aa]. Chest (2021). Medium credibility.

Conclusions

Pulmonary involvement due to Sjögren's is common and frequently involves upper and lower airway disease, parenchymal or interstitial lung disease, and associated lymphoproliferative disease. A common theme for all of these recommendations, and endorsed by the TRG, is the need for a multidisciplinary approach in the care of Sjögren's patients with suspected or confirmed pulmonary complications, including a rheumatologist, primary care physician, pulmonologist, pathologist, radiologist, and, when appropriate, an oncologist.

While most of the evidence would be considered of low quality due to the lack of randomized, placebo-controlled clinical trials, our recommendations and strength of the recommendations incorporate Sjögren's-specific expertise in pulmonology, rheumatology, and hematology/oncology. Thirty-five recommendations were rated as strong, indicating the extent of agreement that these recommendations reflect best practice, while 11 were rated as moderate and six as weak. The lowest level of agreement for any recommendation was 79% for the weak recommendation to consider performing PFTs to detect underlying pulmonary manifestations in asymptomatic Sjögren's patients. CEP comments primarily cited the burden and expense of obtaining PFTs as well as an improbability of non-pulmonologists ordering such tests due to inadequate awareness of and appreciation for pulmonary manifestations in Sjögren's. Overall, the CEP provided a high level of agreement for the recommendations and strength of the recommendations, with 76 of the 102 questions provided for voting receiving higher than 98% agreement.

Clinical practice guidelines for pulmonary manifestations in Sjögren's may improve early identification, evaluation, and uniformity of care by primary care physicians, rheumatologists, and pulmonologists. Full clinical rationales and references developed by the TRG for these recommendations may be viewed in e-Appendix 5. The guidelines process also has led to identification of high priorities for future research (e-Appendix 8). These priorities include epidemiological and risk analyses, blood-based and noninvasive biomarkers, quantitative imaging tools, optimal frequency of repeat PFTs and HRCT testing for each pattern of pulmonary disease, studies on etiology and treatment, and specifically on antifibrotics for Sjögren's-ILD.

---

### Mimics in chest disease: interstitial opacities [^8132d79e]. Insights Into Imaging (2013). Low credibility.

Mimics

The most clinically important mimics of combined cystic and ground-glass pattern are lymphocytic interstitial pneumonia, subacute hypersensitivity pneumonitis and desquamative interstitial pneumonia.

Lymphocytic interstitial pneumonia may present with this combined pattern as the predominant pattern and may occasionally mimic Pneumocystis pneumonia. Distinctive HRCT findings are the thin wall and the more rounded shape of the cysts, the possible associated thickening of the bronchovascular bundles and the mediastinal lymphadenopathy which occurs in 70% of these patients (Fig. 40). Once again, the knowledge of the primary disease from the clinical history causing some degree of immunosuppression (such as Sjogren's disease, AIDS, Castleman's, AIDS, autoimmune disorders or dysproteinemia) gives a strong clue towards LIP.

Fig. 40
Lymphocytic interstitial pneumonia in a female patient with Sjogren's disease. HRCT at the level of the upper lobes exhibits a mixed "ground-glass and cystic pattern" characterised by the presence of diffuse areas of ground-glass opacity and numerous thin-walled rounded and lobulated cysts of variable size

Subacute hypersensitivity pneumonitis (HP) may also manifest with this combined HRCT pattern as the predominant pattern. However, in case of HP the lung cysts are reported to be few in number and thin-walled. The distinctive HRCT finding is characteristic lobular areas of decreased attenuation, even from the inspiratory images and the absence of smoking history, since smokers very rarely develop HP.

Desquamative interstitial pneumonia (DIP) is another entity that may present with this combined pattern. In case of DIP, the diffuse or patchy areas of ground-glass opacity have lower lobe predominance and the scattered "lucencies" may or may not have true walls, either representing "true cysts" or else emphysema or traction bronchiectasis. The patient has to be a smoker based on the clinical history, since DIP develops almost always in heavy smokers (Fig. 41).

Fig. 41
Desquamative interstitial pneumonia. HRCT at the level of the left lower lobe (magnified view of the left lower lobe) reveals a mixed "ground glass and cystic pattern" characterized by the presence of patchy areas of ground glass opacity and numerous small scattered "lucencies" that may represent either true cysts, bronciolectasis or emphysema

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^4832334b]. Chest (2021). High credibility.

Sjögren's respiratory evaluation — algorithm-based assessment specifies that patients without pulmonary symptoms undergo baseline chest radiograph (CXR), clinical reassessment at each visit, and consideration of baseline complete pulmonary function tests (PFTs), noting that the benefit of baseline PFTs in asymptomatic patients is not clear and should be discussed with patients before testing; if normal PFTs and CXR, no further workup with reassessment is advised, whereas abnormal PFTs or CXR prompt high-resolution CT (HRCT) to assess for restriction, abnormal DLco, or abnormal CXR and consideration of HRCT when obstructive defect raises concern for small airways disease. In patients with pulmonary symptoms, the algorithm calls for complete PFTs plus HRCT; if tests are normal, alternate etiologies are considered (including asthma/bronchial hyperreactivity testing, xerotrachea, small airway involvement with repeat expiratory views when not previously obtained, cardiac causes with echocardiogram and/or cardiopulmonary exercise testing, and non-cardiac/non-pulmonary disorders), and if abnormalities are detected, management follows the abnormality identified. Complete PFTs include spirometry, DLco, and lung volumes, ideally measured by body plethysmography.

---

### Pulmonary manifestations of childhood-onset primary Sjögren's syndrome (SS) masquerading as reactive airways disease in a male patient and review of interstitial lung disease associated with SS [^90ce6a54]. Pediatric Rheumatology Online Journal (2022). Medium credibility.

Background

Sjogren syndrome (SS) is a rare chronic autoimmune disease involving exocrine glands and typically presents with sicca syndrome and recurrent parotitis, although extraglandular involvement may occur. Estimate of incidence of primary SS in adults is 3.9–5.3 cases per 100,000 persons with estimated prevalence of 43–282 per 100,000 persons in Europe. Primary SS is more common in women than men with estimates of 9–13 to 1. The classification criteria for primary SS in adults were updated in 2016 by the American College Rheumatology (ACR) and the European League Against Rheumatism (EULAR) with clear data-driven consensus guidelines and weighted criteria. However, given the purpose of classification criteria is standardized definitions for clinical research purposes, classification criteria should not be used for diagnosis in individual cases. There are no established classification or diagnostic criteria for childhood-onset SS.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^29594506]. Chest (2021). High credibility.

Sjögren's-ILD severity and follow-up — disease activity is gauged as "Moderate: shortness of breath on exercise (NYHA II) or PFTs restricted to FVC between 60% and 80% predicted or Dlco between 40% and 70% predicted" and "Severe/high: shortness of breath at rest (NYHA III, IV) or PFTs with FVC < 60% predicted or Dlco < 40% predicted"; pulmonary function tests (PFTs) are repeated after initial evaluation "every 3 to 6 months, especially in the first 1 to 2 years", and "Close follow-up is required for all pharmacological treatments".

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^92f4ceeb]. Chest (2021). High credibility.

Regarding diagnostic investigations for Sjögren's disease, more specifically with respect to pulmonary function testing, PDSS-CEP 2021 guidelines recommend to consider obtaining baseline complete pulmonary function testing for the evaluation of the presence of underlying pulmonary manifestations in patients with SD with no respiratory symptoms. Include pre- and post-bronchodilator spirometry, lung volumes, and diffusing capacity of the lung for CO in the pulmonary function testing. Consider obtaining further corroboration with advanced testing if abnormalities are identified.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^38a60c0f]. Chest (2021). High credibility.

Evaluating for potential Sjögren's in patients with pulmonary symptoms — Table 2 lists patient questions to screen for sicca and systemic features, including "Does your mouth feel dry?", "Do your eyes frequently feel dry, irritated, itchy, or painful?", and "Have you noticed gland swelling in your face or along the jaw line (swollen parotid and/or submandibular glands)?", and notes that such symptoms should prompt further serologic evaluation and/or rheumatology consultation.

---

### Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society / Japanese Respiratory Society clinical practice guideline [^62e92ad9]. American Journal of Respiratory and Critical Care Medicine (2017). Medium credibility.

Question 1 — clinical diagnosis of lymphangioleiomyomatosis (LAM) by high-resolution computed tomography (HRCT) — asks, "Should patients be clinically diagnosed with LAM on the basis of their HRCT findings alone if they have cystic changes in the lung parenchyma that are characteristic of LAM but have no additional confirmatory characteristics of LAM (i.e., clinical, radiologic, or serologic)?" Background notes that "The advent of HRCT of the chest has transformed the field of diffuse cystic lung disease", that "A critical review of HRCT features can often reveal patterns that are diagnostic in a significant proportion of patients with diffuse cystic lung diseases", and defines "The characteristic HRCT pattern of LAM" as "the presence of multiple, bilateral, uniform, round, thin-walled cysts present in a diffuse distribution", adding "It has been suggested that the diagnosis of LAM can be established with a fair degree of certainty on the basis of the presence of characteristic HRCT features alone".

---

### Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights [^1b073d0a]. BMC Pulmonary Medicine (2018). Low credibility.

HRCT, performed as part of the initial assessment of ARF, should be carefully assessed to identify the presence of signs of architectural distortion such as traction bronchiectasis, lung volume loss and honeycombing, considered suggestive of a pre-existing ILD.

Bronchoscopy with bronchoalveolar lavage (BAL) and, in selected cases, lung biopsies may be useful in establishing the diagnosis of the underlying ILD. The indication for bronchoscopic assessment and the choice of the procedure to perform should be carefully discussed in each case, considering ARF severity, the potentially related complications and the risk to trigger an AE.

In unknown ILDs presenting with ARF and in de novo acute ILDs, as shown in the next section, the diagnostic work-up should always include both investigations on primary ILD (autoantibody panel and bronchoscopic procedures when respiratory gas exchange allows it) and investigations on concomitant conditions that may cause ARF, as summarised in Fig. 3.
c) De novo acute ILD presenting with ARF

Fig. 3
Diagnostic work-up in de novo acute ILD and unknown ILD presenting with ARF. Footnotes: ILD = interstitial lung disease; ARF = acute respiratory failure; BAL = bronchoalveolar lavage; TBNA = trans-bronchial needle aspiration

ARF may also represent the clinical onset of a de novo rapidly progressive ILD. In the differential diagnosis the following should be considered: acute interstitial pneumonia (AIP), cryptogenic organizing pneumonia (COP), acute eosinophilic pneumonia (AEP), and drug-induced ILD, and, less frequently, acute hypersensitivity pneumonia, DAH in the setting of a de novo vasculitis, de novo CTD-ILD and lepidic adenocarcinoma with lymphangitic carcinomatosis. AIP, formerly known as Hamman-Rich syndrome, is a rare and fulminant form of diffuse lung injury with a clinical presentation similar to acute respiratory distress syndrome (ARDS), whose etiology remains uncertain. The in-hospital mortality rate is greater than 50% and the majority of patients who survive dies within six months of presentation.

---

### European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases [^e2c50e2c]. The European Respiratory Journal (2022). High credibility.

Regarding diagnostic procedures for connective tissue disease-associated interstitial lung disease, more specifically with respect to surgical lung biopsy, ERS 2022 guidelines recommend to consider performing step-up surgical lung biopsy in patients with undiagnosed ILD and a non-informative transbronchial lung cryobiopsy.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^4b335ca6]. Chest (2021). High credibility.

Regarding medical management for Sjögren's disease, more specifically with respect to management of ILD (systemic corticosteroids), PDSS-CEP 2021 guidelines recommend to consider administering systemic corticosteroids as first-line therapy at a dose based on the clinical context and disease severity, with a standard dose at 0.5–1.0 mg/kg, in patients with SD and symptomatic ILD with moderate-to-severe impairment on lung function, imaging, or in gas-exchange and especially in organizing pneumonia.

---

### European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases [^f1f8653d]. The European Respiratory Journal (2022). High credibility.

Regarding diagnostic procedures for sarcoidosis, more specifically with respect to lung biopsy, ERS 2022 guidelines recommend to consider performing step-up surgical lung biopsy in patients with undiagnosed ILD and a non-informative transbronchial lung cryobiopsy, if obtaining histopathological data is indicated.

---

### Diagnosis of hypersensitivity pneumonitis in adults. An official ATS / JRS / ALAT clinical practice guideline [^9115b3a7]. American Journal of Respiratory and Critical Care Medicine (2020). High credibility.

Regarding diagnostic procedures for hypersensitivity pneumonitis, more specifically with respect to lung biopsy, ALAT/ATS/JRS 2020 guidelines recommend to consider performing transbronchial forceps lung biopsy in patients with newly identified ILD if differential diagnosis includes non-fibrotic HP.

---

### European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases [^4fd345e6]. The European Respiratory Journal (2022). High credibility.

Regarding diagnostic procedures for sarcoidosis, more specifically with respect to lung biopsy, ERS 2022 guidelines recommend to consider performing transbronchial lung cryobiopsy in patients with undiagnosed ILD, whether deemed eligible or ineligible for surgical lung biopsy, if obtaining histopathological data is indicated.

---

### Pulmonary Langerhans cell histiocytosis: the many faces of presentation at initial CT scan [^fb9ddbc5]. Insights Into Imaging (2014). Low credibility.

Fig. 11
Cystic PLCH compared with LAM a, b A 22-year-old woman hospitalised for pneumothorax. Medical history was negative for respiratory disease. Definitive diagnosis of PLCH obtained by VATS performed within a month of imaging. HRCT scans show numerous thin-walled cysts of mostly ovoid and polygonal shape with a nearly imperceptible predominant craniocaudal distribution. Persistence of a small pneumothorax is shown. c, d Biopsy-confirmed LAM in two young female patients. A 3-mm collimated CT scan shows diffuse (c) and mild (d) pulmonary involvement of thin-walled cysts randomly distributed throughout both lungs, with some faint micronodules (arrows) (compare d with Fig. 1)

The cysts of PLCH should be differentiated from the pneumatocoeles which accompany primary pulmonary infections (such as Staphylococcus aureus and P. jiroveci) and that usually resolve with treatment of the underlying infection.

Cystic PLCH must also be differentiated from rare cystic lung diseases, which are mostly associated with peculiar clinical presentations. Lung cysts found in amyloidosis and light-chain deposition disease (LCDD) generally occur in association with multiple myeloma or macroglobulinaemia. In inherited Birt-Hogg-Dubé syndrome, thin walled pulmonary cysts are characteristically found in association with facial papules and an increased risk of developing renal tumours.

Rarely, pulmonary metastasis can be pure cystic in tumours of epithelial origin and, less frequently, in sarcomas. Moreover, cystic PLCH must be differentiated from the rare cystic fibrohistiocytic tumour, both in the primary and in the secondary forms. Pulmonary cysts of this tumour also result from pulmonary nodule transformation. Histological assessment is required for diagnosis.

Scattered cysts can be found in several interstitial lung diseases (ILDs) like lymphocytic interstitial pneumonia (LIP), hypersensitivity pneumonitis (HP) and desquamative interstitial pneumonia (DIP). Diagnosis of these diseases is generally suggested by the typical association of cysts with ground-glass opacities and characteristic pulmonary changes. Moreover, LIP usually occurs with lympho-proliferative or autoimmune disorders, typically representing the most common lung pathology in Sjogren syndrome.

---

### Interstitial lung disease guideline: the British thoracic society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society [^21029b03]. Thorax (2008). Medium credibility.

Regarding diagnostic procedures for idiopathic pulmonary fibrosis, more specifically with respect to lung biopsy, BTS/ITS/TSANZ 2008 guidelines recommend to perform transbronchial lung biopsy as the initial procedure of choice in patients likely to have ILDs in which small samples may be diagnostic, particularly if the disease has a tendency for bronchocentric involvement. Obtain HRCT to guide the biopsy site.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^8e6e6572]. Chest (2021). High credibility.

Interstitial lung disease (ILD) in Sjögren's — prevalence and subtypes are described. The onset of ILD increases over time, with one study showing a prevalence of 10% within the first year of diagnosis and 20% after 5 years. Among Sjögren's patients with ILD, reported subtypes include nonspecific interstitial pneumonia 45%, respiratory bronchiolitis 25%, usual interstitial pneumonia (UIP) 16%, lymphoid interstitial pneumonia 15%, organizing pneumonia 7%, amyloid 6%, and lymphoma 4%.

---

### Imaging-guided chest biopsies: techniques and clinical results [^4f3fd38c]. Insights Into Imaging (2017). Low credibility.

Multiple nodules in a patient without known neoplastic disease or in prolonged remission

Several benign conditions can appear with slowly enlarging or multiple new pulmonary nodules, such as rheumatoid arthritis, sarcoidosis or infectious diseases, including tuberculosis and fungal infections, particularly in immunosuppressed patients. In these cases appropriate clinical work-up and CT follow-up are sufficient to exclude malignancy. Nevertheless multiple nodular lesions may be the initial metastatic presentation in a patient with an unknown primary tumour or the sign of disease progression in a patient with known primary tumour in prolonged remission. In these cases imaging-guided biopsy may be necessary to confirm or exclude malignancy.

Focal parenchymal infiltrates in which an infectious organism cannot be isolated

When infectious organisms cannot be isolated from the culture of sputum, blood or lung lavage, lung biopsy can be necessary to obtain tissue samples for pathological examination. The biopsy sample can be cultured for diagnostic purposes to establish the most appropriate pharmacological treatment. Imaging-guided biopsy was demonstrated to have a sensitivity of 80% and a positive predictive value of 100%.

Diagnosis of hilar masses following negative bronchoscopy

Transbronchial needle aspiration during bronchoscopy or under ultrasound guidance is still considered the reference technique for the diagnosis of hilar masses. However, when bronchoscopy cannot be performed or is inconclusive, hilar masses can be accurately diagnosed by imaging-guided biopsy.

Undiagnosed mediastinal mass

Mediastinal masses are most frequently located in the anterior mediastinum and include a variety of different entities, such as thymic malignancy, lymphomas, endocrine tumours and malignant germ cell tumours. In the absence of typical clinical and imaging features, histological diagnosis is necessary; imaging-guided biopsy should be always attempted in accessible lesions before diagnostic mediastinoscopy or in case of inconclusive results of mediastinoscopy.

Biopsy or re-biopsy of malignancy for targeted therapy

Advanced non-small-cell lung cancer in progression after first-line therapy may need imaging-guided re-biopsy to detect a possible new biological profile and to guide therapeutic decision-making in more than one-third of cases.

---

### 2023 American College of Rheumatology (ACR) / American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases [^df4aebcf]. Arthritis Care & Research (2024). Medium credibility.

Objective

We provide evidence-based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease.

Methods

We developed clinically relevant population, intervention, comparator, and outcomes questions related to screening and monitoring for ILD in patients with SARDs. A systematic literature review was performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A Voting Panel of interdisciplinary clinician experts and patients achieved consensus on the direction and strength of each recommendation.

Results

Fifteen recommendations were developed. For screening people with these SARDs at risk for ILD, we conditionally recommend pulmonary function tests (PFTs) and high-resolution computed tomography of the chest (HRCT chest); conditionally recommend against screening with 6-minute walk test distance (6MWD), chest radiography, ambulatory desaturation testing, or bronchoscopy; and strongly recommend against screening with surgical lung biopsy. We conditionally recommend monitoring ILD with PFTs, HRCT chest, and ambulatory desaturation testing and conditionally recommend against monitoring with 6MWD, chest radiography, or bronchoscopy. We provide guidance on ILD risk factors and suggestions on frequency of testing to evaluate for the development of ILD in people with SARDs.

Conclusion

This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the screening and monitoring of ILD in people with SARDs.

---

### Transbronchial biopsy is useful in predicting UIP pattern [^f07218ab]. Respiratory Research (2012). Low credibility.

Conclusion

In summary, we conclude that TBB can diagnose UIP in a portion of such patients. In the appropriate clinical-radiological setting, TBB showing at least two histopathological criteria of UIP reliably diagnoses UIP pattern. Even for cases with only one criterion TBB appears to be informative, but with a lower predictive value.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^b6cb4cc8]. Chest (2021). High credibility.

Regarding diagnostic investigations for Sjögren's disease, more specifically with respect to pulmonary function testing, PDSS-CEP 2021 guidelines recommend to obtain baseline pulmonary function testing in all patients with SD and suspected or established ILD, and follow-up initially at 3- to 6-month intervals for at least 1 year. Take into consideration the type of ILD, the clinical course, and the pace of change noted on the serial pulmonary function testing for subsequent testing. Include lung volumes by body plethysmography, spirometry, diffusing capacity, and oxygen saturations at rest and exercise in baseline pulmonary function testing.

---

### Diagnosis of hypersensitivity pneumonitis in adults. An official ATS / JRS / ALAT clinical practice guideline [^f38136f4]. American Journal of Respiratory and Critical Care Medicine (2020). High credibility.

Regarding diagnostic procedures for hypersensitivity pneumonitis, more specifically with respect to lung biopsy, ALAT/ATS/JRS 2020 guidelines recommend to consider performing transbronchial lung cryobiopsy in patients with newly identified ILD if differential diagnosis includes fibrotic HP.

---

### Diagnosis of hypersensitivity pneumonitis in adults. An official ATS / JRS / ALAT clinical practice guideline [^b8b05d00]. American Journal of Respiratory and Critical Care Medicine (2020). High credibility.

Regarding diagnostic procedures for hypersensitivity pneumonitis, more specifically with respect to lung biopsy, ALAT/ATS/JRS 2020 guidelines recommend to insufficient evidence to recommend for or against transbronchial lung cryobiopsy in patients with newly identified ILD if differential diagnosis includes non-fibrotic HP.

---

### Bronchoscopy assisting-2007 revision&update [^6a602a71]. AARC (2007). Medium credibility.

Bronchoscopy assisting — contraindications — Flexible bronchoscopy should be performed only when the relative benefits outweigh the risks.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^cf8dbd6a]. Chest (2021). High credibility.

Regarding nonpharmacologic interventions for Sjögren's disease, more specifically with respect to air humidification, PDSS-CEP 2021 guidelines recommend to consider advising humidification in patients with SD having dry, nonproductive cough after exclusion of other causes.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^161cc760]. Chest (2021). High credibility.

Regarding diagnostic investigations for Sjögren's disease, more specifically with respect to history and physical examination, PDSS-CEP 2021 guidelines recommend to obtain oximetry testing as part of the initial evaluation of patients with SD and suspected ILD.

---

### Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society / Japanese Respiratory Society clinical practice guideline [^b5742361]. American Journal of Respiratory and Critical Care Medicine (2017). Medium credibility.

Transbronchial lung biopsy (TBLB) performance and safety in LAM — Transbronchial lung biopsy has an estimated yield of greater than 50% for the diagnosis of LAM, and the guideline panel weighed the estimated diagnostic yield (50%) versus the complication rate (2–14%) and cost of bronchoscopy. Reported bronchoscopy complication data note that the risk of any complication was 14% in the largest case series but is generally estimated to be approximately 2%, and although pneumothorax is a theoretical concern in cystic lung disease, the pneumothorax rate of 0 to 6% is comparable to the general population. In contrast, VATS-guided surgical lung biopsy risks include a 1.5 to 4.5% mortality rate and 10 to 19% procedure-related complication rate. Consultation with an expert center is recommended when transbronchial biopsy is being considered and for interpretation.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^33308696]. Chest (2021). High credibility.

Regarding diagnostic investigations for Sjögren's disease, more specifically with respect to echocardiography, PDSS-CEP 2021 guidelines recommend to obtain echocardiography in patients with SD having dyspnea in the following circumstances:

- suspected pulmonary hypertension

- unexplained dyspnea after pulmonary etiologies (asthma, small airway disease, bronchiectasis, ILD) have been excluded

- suspected cardiac involvement.

---

### Diagnosis of idiopathic pulmonary fibrosis. An official ATS / ERS / JRS / ALAT clinical practice guideline [^e49ae7c9]. American Journal of Respiratory and Critical Care Medicine (2018). Medium credibility.

Regarding diagnostic procedures for idiopathic pulmonary fibrosis, more specifically with respect to lung biopsy, ALAT/ATS/ERS/JRS 2018 guidelines recommend to insufficient evidence to recommend for or against transbronchial lung biopsy or lung cryobiopsy in patients with probable usual interstitial pneumonia, indeterminate usual interstitial pneumonia, or alternative diagnosis on HRCT.

---

### Diagnosis of idiopathic pulmonary fibrosis. An official ATS / ERS / JRS / ALAT clinical practice guideline [^3ab11933]. American Journal of Respiratory and Critical Care Medicine (2018). Medium credibility.

Usual interstitial pneumonia imaging — high-resolution computed tomography (CT) shows honeycombing with subpleural and basal predominance, often with concurrent mild ground-glass opacity, and honeycombing characterized by clustered cystic airspaces with well-defined walls and variable diameters that can appear in single or multiple layers.

---

### Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS / ERS / JRS / ALAT clinical practice guideline [^72ca5a59]. American Journal of Respiratory and Critical Care Medicine (2022). High credibility.

Regarding diagnostic investigations for connective tissue disease-associated interstitial lung disease, more specifically with respect to laboratory testing, other tests, ALAT/ATS/ERS/JRS 2022 guidelines recommend to insufficient evidence to recommend for or against the addition of genomic classifier testing for the diagnosis of usual interstitial pneumonia in patients with ILD of undetermined type undergoing transbronchial forceps biopsy.

---

### Diagnosis of idiopathic pulmonary fibrosis. An official ATS / ERS / JRS / ALAT clinical practice guideline [^8f49b86b]. American Journal of Respiratory and Critical Care Medicine (2018). Medium credibility.

Regarding diagnostic procedures for idiopathic pulmonary fibrosis, more specifically with respect to lung biopsy, ALAT/ATS/ERS/JRS 2018 guidelines recommend to do not perform surgical or transbronchial lung biopsy in patients with definite usual interstitial pneumonia on HRCT.

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^c28a7e63]. Chest (2021). High credibility.

Symptomatic/moderate-severe ILD — second-line maintenance options: If initial treatment with MMF or azathioprine is insufficient or not tolerated in Sjögren's patients with ILD who are symptomatic and in whom PFTs or HRCT demonstrated moderate-severe impairment, subsequent second-line maintenance drugs may include rituximab and calcineurin inhibitors, cyclosporine, or tacrolimus.

---

### Official American Thoracic Society / Japanese Respiratory Society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management [^745ac823]. American Journal of Respiratory and Critical Care Medicine (2016). Medium credibility.

Regarding diagnostic investigations for tuberous sclerosis complex, more specifically with respect to evaluation of pulmonary involvement, lung biopsy, ATS/JRS 2016 guidelines recommend to consider performing transbronchial lung biopsy before surgical lung biopsy when a definitive diagnosis is required in patients with parenchymal cysts on HRCT characteristic of lymphangioleiomyomatosis but not having additional confirmatory features of lymphangioleiomyomatosis (clinical, radiologic or serologic).

---

### Consensus guidelines for evaluation and management of pulmonary disease in Sjögren's [^30beb7fe]. Chest (2021). Medium credibility.

Background

Pulmonary disease is a potentially serious yet underdiagnosed complication of Sjögren's syndrome, the second most common autoimmune rheumatic disease. Approximately 16% of patients with Sjögren's demonstrate pulmonary involvement with higher mortality and lower quality of life.

Research Question

Clinical practice guidelines for pulmonary manifestations of Sjögren's were developed by the Sjögren's Foundation after identifying a critical need for early diagnosis and improved quality and consistency of care.

Study Design and Methods

A rigorous and transparent methodology was followed according to American College of Rheumatology guidelines. The Pulmonary Topic Review Group (TRG) developed clinical questions in the PICO (Patient, Intervention, Comparison, Outcome) format and selected literature search parameters. Each article was reviewed by a minimum of two TRG members for eligibility and assessment of quality of evidence and strength of recommendation. Guidelines were then drafted based on available evidence, expert opinion, and clinical importance. Draft recommendations with a clinical rationale and data extraction tables were submitted to a Consensus Expert Panel for consideration and approval, with at least 75% agreement required for individual recommendations to be included in the final version.

Results

The literature search revealed 1,192 articles, of which 150 qualified for consideration in guideline development. Of the original 85 PICO questions posed by the TRG, 52 recommendations were generated. These were then reviewed by the Consensus Expert Panel and 52 recommendations were finalized, with a mean agreement of 97.71% (range, 79%-100%). The recommendations span topics of evaluating Sjögren's patients for pulmonary manifestations and assessing, managing, and treating upper and lower airway disease, interstitial lung disease, and lymphoproliferative disease.

Interpretation

Clinical practice guidelines for pulmonary manifestations in Sjögren's will improve early identification, evaluation, and uniformity of care by primary care physicians, rheumatologists, and pulmonologists. Additionally, opportunities for future research are identified.